United States Pulmonary Arterial Hypertension Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The global Pulmonary arterial hypertension market size reached US$ 8.04 Billion in 2024 from US$ 7.59 Billion in 2023 and is expected to reach US$ 14.11 Billion by 2033, growing at a CAGR of 6.5% during the forecast period 2025-2033.

Key Development:

United States: Recent Industry Developments

✅ In June 2025, Merck announced that its Phase 3 HYPERION study of WINREVAIRTM (sotatercept-csrk) met the primary endpoint in recently diagnosed adults with PAH, significantly reducing the risk of clinical worsening events.

✅ In June 2025, United Therapeutics Corporation concluded enrollment in the ADVANCE OUTCOMES study of ralinepag, aiming to be the first once-daily oral prostacyclin agonist for PAH patients.

✅ In June 2025, Liquidia Corporation launched YUTREPIA, a novel inhaled treprostinil formulation for PAH, initiating shipments to U.S. customers.

Japan: Recent Industry Developments

✅ In July 2025, Pahr Therapeutics raised $14 million in seed funding to accelerate its mission of developing cutting-edge therapies for pulmonary arterial hypertension (PAH).

✅ In July 2025, Pahr Therapeutics secured $14 million in seed financing to advance innovative treatments for PAH, with backing from AN Venture Partners, RA Capital Management, and University of Tokyo Edge Capital Partners (UTEC).

✅ In March 2025, Nippon Shinyaku launched Uptravi® tablets for pediatric 0.05 mg, expanding treatment options for PAH in children.

Others

✅ In August 2025, Natco Pharma launched oral suspension tablets used in the treatment of pulmonary arterial hypertension (PAH). In an exchange filing, the company said it has launched Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Tracleer by Actelion Pharmaceuticals US Inc. NATCO's marketing partner for the product is Lupin Ltd. Bosentan tablets are used for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in paediatric patients aged three years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/pulmonary-arterial-hypertension-market?sb

Pulmonary arterial hypertension (PAH) is a progressive condition characterized by high blood pressure in the arteries connecting the heart to the lungs, leading to shortness of breath, fatigue, and heart strain. Treatments include prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase inhibitors to improve blood flow, reduce symptoms, and slow disease progression.

Recent Mergers and acquisitions:

United States: Recent M&A Activity in PAH

✅ In September 2025, Gossamer Bio entered into an option agreement to acquire Respira Therapeutics and its lead candidate, RT234, an inhaled, on-demand vardenafil for PAH and PH-ILD. This strategic move aims to enhance Gossamer's portfolio in pulmonary hypertension therapeutics.

✅ In March 2025, Inhibikase Therapeutics acquired CorHepta, a clinical-stage company developing therapies for PAH. This acquisition strengthens Inhibikase's pipeline, particularly in cardiopulmonary diseases.

✅ In October 2024, XOMA Royalty acquired Pulmokine for $20 million, gaining royalty and milestone interests in seralutinib, a Phase 3 asset for PAH. This acquisition adds a promising asset to XOMA's portfolio.

Key Players:

=> Johnson & Johnson,United Therapeutics Corporation, Bayer AG, Gilead Sciences, Inc., Viatris Inc., Merck & Co., Inc., Liquidia Corporation

Growth Forecast Projected:

The Global Pulmonary arterial hypertension Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2033. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Pulmonary arterial hypertension Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=pulmonary-arterial-hypertension-market

Key Segments:

➥ By Drug Class: Prostacyclin & Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase-5 (PDE-5) Inhibitors, Endothelin Receptor Antagonists (ERA), Others
➥ By Route of Administration: Inhalation, Subcutaneous, Intravenous, Oral
➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis for Pulmonary arterial hypertension Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Pulmonary arterial hypertension producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Pulmonary arterial hypertension revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pulmonary-arterial-hypertension-market?sb

FAQ

What is the current size of the Pulmonary arterial hypertension Market?

A: In 2024, the Pulmonary arterial hypertension Market was valued at US$ 8.04 Billion, reflecting its strong industry presence.

Q2: How large is the Pulmonary arterial hypertension Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Pulmonary arterial hypertension Market will grow to around US$ 14.11 Billion , demonstrating significant expansion.

Q3: What is the growth rate of the Pulmonary arterial hypertension Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 6.5% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.